March 25, 2017, Cuu Long Pharmaceutical JSC (DCL) held a groundbreaking ceremony to build capsules plant 3. The project has a total investment of 357 billion, divided to 3 phases, and expected starting its operation from Q4/2017.
Speaking at the ceremony, Mr. Nguyen Van Sang, Chairman and CEO of company said, this is an important milestone in the empowerment of DCL, continue to maintain and strengthen the throne No. 1 in Vietnam in the field of manufacturing empty capsules. “In the past year, two plants of DCL were always maximum their operating capacity but still did not meet the needs of both domestic and international market. Facing this situation, in recent years, with strategic support from the FIT Group, DCL leaders had researched and planed for investment of expanding capsule factory. The investment of plant expansion will help raise more than tripling current production capacity, not only to better meet customer needs, but also contribute to creating more jobs for labor and contribute to the local budget, “Mr Sang said.
Cuu Long Pharmaceutical JSC currently has charter capital of over 563 billion. The company currently has two factories operating in this field, including No. 1 capsule factory operating since 1999 with a capacity of 1.8 billion / year; plant No. 2 has been invested since 2008 with a capacity of 2 billion / year. Cuu Long Pharmaceutical holds the No. 1 market share position in the array of capsules.
Not only holds No. 1 capsule array, Cuu Long Pharmaceutical is one of the largest pharmaceutical companies in Vietnam and consumable medical supplies. Since early 2017, company successfully acquired Euvipharm Pharmaceutical JSC – a corporate member of d Valeant – one largest pharmaceutical company in Canada; and establised Benovas oncology JSC. With the expansion of this activity, Cuu Long Pharmaceutical aims to become the number one pharmaceutical company in Vietnam in next 5 years.
In 2017, company target to achieve 914 billion in sales and 96 billion profit after tax; respectively up to 24% and 7% over the figure achieved in 2016.
